LU85877A1 - PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF COLITIS AND COLOPATHIES - Google Patents
PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF COLITIS AND COLOPATHIES Download PDFInfo
- Publication number
- LU85877A1 LU85877A1 LU85877A LU85877A LU85877A1 LU 85877 A1 LU85877 A1 LU 85877A1 LU 85877 A LU85877 A LU 85877A LU 85877 A LU85877 A LU 85877A LU 85877 A1 LU85877 A1 LU 85877A1
- Authority
- LU
- Luxembourg
- Prior art keywords
- pharmaceutical composition
- cade
- colitis
- essence
- essential oil
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 206010009887 colitis Diseases 0.000 title claims description 8
- 241000246358 Thymus Species 0.000 claims description 12
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 12
- 239000001585 thymus vulgaris Substances 0.000 claims description 12
- 239000000341 volatile oil Substances 0.000 claims description 11
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000007903 gelatin capsule Substances 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims 1
- 244000309465 heifer Species 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ACTOXUHEUCPTEW-CEUOBAOPSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-CEUOBAOPSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000224421 Heterolobosea Species 0.000 description 1
- 241000721662 Juniperus Species 0.000 description 1
- 241000981924 Juniperus oxycedrus Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 210000003001 amoeba Anatomy 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical class [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000001354 painful effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Ο- JL·Ο- JL ·
Le présente invention est relative à une imposition pharmaceutique pour le traitement de c°lites et colopathies.The present invention relates to pharmaceutical taxation for the treatment of cites and colopathies.
55
On sait gue le système digestif, en particulier ^-'intestion grêle et le cêlon, est le siège d'une série d'affections, souvent chroniques, que l'on qualifie, en Sênêral, de grêlites, colites ou colopathies. Il s'-agit de maladies infectieuses, parasitaires ou fonctionnelles, dues souvent ê divers microorganismes tels que colibacilles, ascaris, amibes, etc... ou à un dysfonctionnement qui se manifestent principalement par de la constipation et/ou de la diarrhée accompagnées de douleurs abôominales et d'autres troubles, tels que céphalée, insomnie, voire même troubles psychiques.We know that the digestive system, in particular the small intestine and the colon, is the site of a series of affections, often chronic, which we qualify, in Senegal, as hailitis, colitis or colopathy. These are infectious, parasitic or functional diseases, often due to various microorganisms such as colibacilli, roundworms, amoebas, etc. ... or to a dysfunction which manifests itself mainly by constipation and / or diarrhea accompanied by abdominal pain and other disorders, such as headache, insomnia, and even mental illness.
Il est connu de traiter les colites et colopathies à l'aide de divers médicaments, notamment des antibiotiques comme la rovamycine, i?émétine et divers dérivés 20 haiogênès ou arsénicaux de la quinoléine, de même qu'au moyen de pansements à base de composés de bismuth. Ces médicaments connus ont, en général, des effets secondaires indésirables. Ils provoquent souvent un déséquilibre de la flore intestinale et parfois 25 d'autres troubles notamment au niveau oculaire.It is known to treat colitis and colopathies using various drugs, including antibiotics such as rovamycin, emetine and various halogen or arsenic derivatives of quinoline, as well as with dressings based on compounds. of bismuth. These known drugs generally have undesirable side effects. They often cause an imbalance in the intestinal flora and sometimes other disorders, particularly in the eye.
La présente invention concerne une composition pharmaceutique dépourvue de ces effets secondaires, 30 convenant spécialement pour ^.e traitement de diverses .The present invention relates to a pharmaceutical composition devoid of these side effects, especially suitable for the treatment of various.
2 formes de colites et colopathies,2 forms of colitis and colopathies,
La composition pharmaceutique suivant la présente 5 invention se caractérise essentiellement par le fait qu’elle contient, comme principes actifs, de l'essence de thym et de l'huile essentielle de cade.The pharmaceutical composition according to the present invention is essentially characterized by the fact that it contains, as active principles, thyme essence and cade essential oil.
L’essence de thym est une essence aromatique 10 contenant du thymol obtenue par traitement de la plante Thymus vulgaris, par distillation avec de l'eau, par chauffage c la vapeur d’eau et condensation.The essence of thyme is an aromatic essence containing thymol 10 obtained by treatment of the plant Thymus vulgaris, by distillation with water, by heating c water vapor and condensation.
Quant à l’huile essentielle de cade, il s'agit 15 d'un mélange de produits de distillation du bois de génêvrier oxycèôre (Juniperus oxycedrus), dont l'emploi est connu dans le traitement d'affections cutanées, telles que le psoriasis et certains eczémas.As for cade essential oil, it is a mixture of distillation products of juniper wood (Juniperus oxycedrus), the use of which is known in the treatment of skin conditions, such as psoriasis. and some eczema.
20 Conformément à la présente invention, la composition pharmaceutique contient, à titre d'ingrédients actifs, de l'essence de thym à raison d ’ environ 0,1 t 70 % eu perds,. ainsi que de l'huile essentielle de cade t environ 0,1 è 40 % en poids, par 25 rapport au poids total de la composition.In accordance with the present invention, the pharmaceutical composition contains, as active ingredients, thyme essence in an amount of approximately 0.1% to 70% lost. as well as cade essential oil about 0.1 to 40% by weight, relative to the total weight of the composition.
La proportion d'essence de thym est, de préférence, comprise entre environ 2 et 20 % du poids 30 de la composition totale, tandis eue la orotOrtion d'huile essentielle de cade est avantageusement comprise entre C,2 et 10 % du poids de la composition totale, cette dernière contenant de préférence une quantité d'essence ce thym, supérieure è celle d'huile | t-f · t < £ 3 de cade.The proportion of thyme essence is preferably between approximately 2 and 20% of the weight of the total composition, while the orotOrtion of cade essential oil is advantageously between C, 2 and 10% of the weight of the total composition, the latter preferably containing a quantity of thyme essence, greater than that of oil | t-f · t <£ 3 of cade.
Pour une unité posologique de 0,5 g, la 5 composition pharmaceutique contient de 0,5 è 350 mg, de préférence de 2 à 100 mg d'essence de thym et de 0,5 à 200 mg, de préférence, de 1 t 75 mg d'huile essentielle de cade.For a dosage unit of 0.5 g, the pharmaceutical composition contains from 0.5 to 350 mg, preferably from 2 to 100 mg of thyme essence and from 0.5 to 200 mg, preferably from 1 t 75 mg of cade essential oil.
10 La composition pharmaceutique suivant 1’invention peut évidemment contenir des excipients classiques.The pharmaceutical composition according to the invention can obviously contain conventional excipients.
Elle peut se présenter sous diverses formes galéniques è administrer par la bouche.It can come in various dosage forms to be administered by mouth.
15 La composition pharmaceutique se présente, de préférence, sous forme de capsules molles ou dures, telles que des capsules de gélatine, contenant les deux ingrédients actifs. Cependant, elle peut aussi se présenter sous forme de sirop, de suspensions aqueuses, 20 voire même sous forme de préparations solides, telles que des comprimés ou dragées entériques.The pharmaceutical composition is preferably in the form of soft or hard capsules, such as gelatin capsules, containing the two active ingredients. However, it can also be in the form of syrup, aqueous suspensions, or even in the form of solid preparations, such as tablets or enteric dragees.
Les exemples non limitatifs suivants illustrent des compositions pharmaceutiques suivant 1 * invention.The following nonlimiting examples illustrate pharmaceutical compositions according to the invention.
25 EXEMPLE 125 EXAMPLE 1
Dans une capsule de gélatine molle, or. introduit, 30 en plus d'un excipient aqueux, de l'essence de thym et de l'huile essentielle de cade dans les proportions suivantes : j î f * / essence de thym : 65 mg huile essentielle de cade s 7 mg excipient q.s. ad C,5 mg 5 EXEMPLE 2 essence de thym : 25 mg 10 huile essentielle de cade : 1 mg excipient aqueux q.s. ad 0,5 g pour une capsule de gélatine molle.In a soft gelatin capsule, gold. introduces, in addition to an aqueous excipient, thyme essence and cade essential oil in the following proportions: i f * / thyme essence: 65 mg cade essential oil s 7 mg excipient q.s. ad C, 5 mg 5 EXAMPLE 2 essence of thyme: 25 mg 10 essential oil of cade: 1 mg aqueous excipient q.s. ad 0.5 g for one soft gelatin capsule.
15 Des essais ont révélé que l'administration de 1 à 4 capsules par jour permet de faire disparaître en quelques jours les symptômes et effets douloureux de divers types de colites ou colopathies, en particulier les colites dues t des bactéries ou parasites 20 pathogènes, ainsi que les colites spasmodiques.15 Tests have revealed that the administration of 1 to 4 capsules per day makes it possible to disappear in a few days the symptoms and painful effects of various types of colitis or colopathies, in particular colitis due to pathogenic bacteria or parasites, as well as than spasmodic colitis.
Ces essais ont démontré que la composition pharmaceutique suivant l'invention respecte l'équilibre de la flore intestinale et possède une remarquable activité 25 antisossmoaioue.These tests demonstrated that the pharmaceutical composition according to the invention respects the balance of the intestinal flora and has a remarkable antisossmoaioue activity.
!!
Claims (5)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU85877A LU85877A1 (en) | 1985-05-06 | 1985-05-06 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF COLITIS AND COLOPATHIES |
| FR868601950A FR2581311B1 (en) | 1985-05-06 | 1986-02-13 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF COLITIS AND COLOPATHIES, BASED ON THYME ESSENCE AND CADE ESSENTIAL OIL |
| CH1724/86A CH667391A5 (en) | 1985-05-06 | 1986-04-28 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF COLITIS AND COLOPATHIES. |
| DE19863615031 DE3615031A1 (en) | 1985-05-06 | 1986-05-02 | PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF COLITIS AND COLOPATHIA |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU85877 | 1985-05-06 | ||
| LU85877A LU85877A1 (en) | 1985-05-06 | 1985-05-06 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF COLITIS AND COLOPATHIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU85877A1 true LU85877A1 (en) | 1986-12-05 |
Family
ID=19730455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU85877A LU85877A1 (en) | 1985-05-06 | 1985-05-06 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF COLITIS AND COLOPATHIES |
Country Status (4)
| Country | Link |
|---|---|
| CH (1) | CH667391A5 (en) |
| DE (1) | DE3615031A1 (en) |
| FR (1) | FR2581311B1 (en) |
| LU (1) | LU85877A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4213167C2 (en) * | 1992-04-22 | 1995-10-05 | Suekrettin Dr Med Guelduetuna | Medicines to control Helicobacter pylori |
| IL102313A (en) * | 1992-06-25 | 1996-12-05 | Technion Res & Dev Foundation | Method for inhibiting growth of helicobacter pylori |
| FR2872683B1 (en) * | 2004-07-12 | 2008-08-01 | Tech Animales Sa Bureau Des | FOOD ADDITIVE FOR IMPROVING THE ZOOTECHNIC PERFORMANCE OF POULTRY |
-
1985
- 1985-05-06 LU LU85877A patent/LU85877A1/en unknown
-
1986
- 1986-02-13 FR FR868601950A patent/FR2581311B1/en not_active Expired - Lifetime
- 1986-04-28 CH CH1724/86A patent/CH667391A5/en not_active IP Right Cessation
- 1986-05-02 DE DE19863615031 patent/DE3615031A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| DE3615031A1 (en) | 1986-11-06 |
| FR2581311A1 (en) | 1986-11-07 |
| FR2581311B1 (en) | 1990-06-01 |
| CH667391A5 (en) | 1988-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2680433C (en) | Novel composition based on cholest-4-ene-3-one oxime | |
| CA2642850C (en) | Combination of alpha-2 receptor agonist (clonidine) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea | |
| FR2774591A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING METFORMIN AND FIBRATE COMBINATION AND USE THEREOF FOR THE PREPARATION OF MEDICAMENTS FOR REDUCING HYPERGLYCEMIA | |
| JPH0137398B2 (en) | ||
| BE895724A (en) | NEW THERAPEUTIC USE OF DIHYDROCYCLOSPORIN D | |
| FR2802414A1 (en) | COMPOSITION, ESPECIALLY COSMETIC OR DERMATOLOGICAL, CONTAINING OLIGOSACCHARIDES, METHOD FOR THE PREPARATION THEREOF AND METHOD FOR THE COSMETIC TREATMENT | |
| CA2283122A1 (en) | Plant extract compositions, method of preparation, and pharmaceutical compositions containing them | |
| FR2581311A1 (en) | Pharmaceutical compositions for the treatment of colites and colopathies, based on thyme oil and cade essential oil. | |
| FR2624012A1 (en) | Novel pharmaceutical compositions having a hypnotic action based on chloral hydrate | |
| CH664284A5 (en) | Chloroquine medicaments without bitter taste - contain complex of chloroquine with copolymer of methacrylic] acid and methyl methacrylate] | |
| EP0920320A2 (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, a strong base and tromethamol | |
| US6475520B1 (en) | Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation | |
| FR2820423A1 (en) | 3,4-DIAMINOPYRIDINE TARTRATE AND PHOSPHATE, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| FR2823M (en) | ||
| EP0086680B1 (en) | Strong anti-asthenic compositions containing a double salt of ascorbic acid and amino-diacids | |
| CH678275A5 (en) | ||
| JPS5980608A (en) | Transparent liquid laxative composition | |
| EP0038060B1 (en) | A pharmaceutical composition for treating hypertension containing l-alpha-methyl-3,4-dihydroxyphenylalanine and salicylamide | |
| KR950005869B1 (en) | Therapeutic agent for gastritis | |
| RU2163137C1 (en) | Agent enhancing work capacity and preventing immunity decrease | |
| FR2768055A1 (en) | USE OF SULFONANILIDE DERIVATIVES FOR OBTAINING A MEDICAMENT FOR THE TREATMENT OF RETROGRADE EJACULATION OR ASPPERMIA | |
| LU84827A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE POLYFLUORINATED ALCOHOL | |
| EP0194178A1 (en) | Pharmaceutical compositions of betaxolol and nifedipine | |
| FR2646352A1 (en) | Novel pharmaceutical compositions for the treatment of constipation and process for obtaining them | |
| WO1984004249A2 (en) | Composition having an improved pharmaceutical activity and utilisation thereof in veterinary medecine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DT | Application date | ||
| TA | Annual fee |